What is it about?
The manuscript describes the preparation and evaluations of salts of linogliride with intended solubilities less than linogliride free base and linogliride fumarate. The fumarate salt form was in clinical evaluation as an immediate release dosage form intended for the treatment of Type 2 insulin dependent diabetes. The pH solubility profiles and intrinsic dissolution rates of the salts were determined. The results supported the use of one or more of the salts in an extended release dosage form.
Featured Image
Why is it important?
There are several mechanisms for creating extended release. Most of them involve resources such as pH dependent polymers, slowly releasing polymers and complicated systems and osmotic pumps.. Salt forms can be employed without the addition of these resources, using existing resources.
Perspectives
Interestingly, this work was conducted at a time when extended release was not considered appropriate for insulin dependent diabetes. However, extended release products for diabetes control are on the market and prescribed regularly.
Dr. Frank A Chrzanowski
ExpertPharma, LLC
Read the Original
This page is a summary of: The preparation and evaluation of salt forms of linogliride with reduced solubilities as candidates for extended release, Drug Development and Industrial Pharmacy, November 2016, Taylor & Francis,
DOI: 10.1080/03639045.2016.1257019.
You can read the full text:
Contributors
The following have contributed to this page
